Our findings of the gross overexpression of TRIB2 by enzalutamide treatment and the aggressive growth characteristics of TRIB2-OE cells signify a negative impact of AR blockade therapy for prostate cancer. The gene discussed is TRIB2; the disease is Familial prostate cancer.